{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T04:16:39Z","timestamp":1788149799151,"version":"build-2803163510"},"reference-count":58,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.es","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Medicina Cl\u00ednica"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.medcli.2026.107537","type":"journal-article","created":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T12:21:07Z","timestamp":1784550067000},"page":"107537","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Optimizaci\u00f3n de la duraci\u00f3n del tratamiento antimicrobiano en la era de los programas de optimizaci\u00f3n de antimicrobianos"],"prefix":"10.1016","volume":"166","author":[{"given":"Cristina","family":"Rodr\u00edguez-Urbistondo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 Miguel","family":"Cisneros","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.medcli.2026.107537_bib0005","doi-asserted-by":"crossref","first-page":"2061","DOI":"10.1093\/jac\/dkaf167","article-title":"World Health Organisation's Bacterial Pathogen Priority List (BPPL) 2017 and BPPL 2024 to combat global antimicrobial resistance crisis: \u2018challenges and opportunities.\u2019","volume":"80","author":"Krishnaprasad","year":"2025","journal-title":"J Antimicrob Chemother."},{"key":"10.1016\/j.medcli.2026.107537_bib0010","doi-asserted-by":"crossref","first-page":"101220","DOI":"10.1016\/j.lanepe.2025.101220","article-title":"Burden of bacterial antimicrobial resistance among hospitalised patients in Spain: findings from three nationwide prospective studies","volume":"51","author":"Pe\u00f1alva","year":"2025","journal-title":"Lancet Reg Health Eur."},{"key":"10.1016\/j.medcli.2026.107537_bib0015","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1016\/S0140-6736(20)30677-2","article-title":"Fertility, mortality, migration, and population scenarios for 195 countries and territories from 2017 to 2100: a forecasting analysis for the Global Burden of Disease Study","volume":"396","author":"Vollset","year":"2020","journal-title":"Lancet."},{"key":"10.1016\/j.medcli.2026.107537_bib0020","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1016\/S0140-6736(24)01867-1","article-title":"Global burden of bacterial antimicrobial resistance 1990-2021: a systematic analysis with forecasts to 2050","volume":"404","author":"Naghavi","year":"2024","journal-title":"Lancet."},{"key":"10.1016\/j.medcli.2026.107537_bib0025","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1017\/ice.2023.102","article-title":"SHEA\/IDSA\/APIC Practice Recommendation: Strategies to prevent methicillin-resistant Staphylococcus aureus transmission and infection in acute-care hospitals: 2022 Update","volume":"44","author":"Popovich","year":"2023","journal-title":"Infect Control Hosp Epidemiol."},{"key":"10.1016\/j.medcli.2026.107537_bib0030","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1002\/bies.201400153","article-title":"Mutational heterogeneity: a key ingredient of bet-hedging and evolutionary divergence?.: The broad spectrum of mutations and their flexible frequency in populations provides a source of risk avoidance and alternative evolutionary strategies","volume":"37","author":"Ferenci","year":"2015","journal-title":"Bioessays."},{"key":"10.1016\/j.medcli.2026.107537_bib0035","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1128\/AAC.05760-11","article-title":"High-level cefixime- and ceftriaxone-resistant Neisseria gonorrhoeae in France: novel penA mosaic allele in a successful international clone causes treatment failure","volume":"56","author":"Unemo","year":"2012","journal-title":"Antimicrob Agents Chemother."},{"key":"10.1016\/j.medcli.2026.107537_bib0040","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/S0140-6736(15)00473-0","article-title":"Understanding the mechanisms and drivers of antimicrobial resistance","volume":"387","author":"Holmes","year":"2016","journal-title":"Lancet."},{"key":"10.1016\/j.medcli.2026.107537_bib0045","doi-asserted-by":"crossref","first-page":"20316","DOI":"10.2807\/ese.17.46.20316-en","article-title":"The European Centre for Disease Prevention and Control (ECDC) pilot point prevalence survey of healthcare-associated infections and antimicrobial use","volume":"17","author":"Zarb","year":"2012","journal-title":"Euro Surveill."},{"key":"10.1016\/j.medcli.2026.107537_bib0050","doi-asserted-by":"crossref","first-page":"2551","DOI":"10.1016\/S0140-6736(24)01019-5","article-title":"Ensuring progress on sustainable access to effective antibiotics at the 2024 UN General Assembly: a target-based approach","volume":"403","author":"Mendelson","year":"2024","journal-title":"Lancet."},{"key":"10.1016\/j.medcli.2026.107537_bib0055","doi-asserted-by":"crossref","first-page":"2439","DOI":"10.1016\/S0140-6736(24)00862-6","article-title":"Burden of bacterial antimicrobial resistance in low-income and middle-income countries avertible by existing interventions: an evidence review and modelling analysis","volume":"403","author":"Lewnard","year":"2024","journal-title":"Lancet."},{"key":"10.1016\/j.medcli.2026.107537_bib0060","unstructured":"Agrosynergie, COGEA, Directorate-General for Agriculture and Rural Development (European Commission), Or\u00e9ade-Br\u00e8che. Study on CAP Measures and Instruments Promoting Animal Welfare and Reduction of Antimicrobials Use: Executive Summary. Publications Office of the European Union; 2022."},{"key":"10.1016\/j.medcli.2026.107537_bib0065","doi-asserted-by":"crossref","first-page":"1992","DOI":"10.1093\/cid\/cix692","article-title":"Long-Term Impact of an Educational Antimicrobial Stewardship Program on Hospital-Acquired Candidemia and Multidrug-Resistant Bloodstream Infections: A Quasi-Experimental Study of Interrupted Time-Series Analysis","volume":"65","author":"Molina","year":"2017","journal-title":"Clin Infect Dis."},{"key":"10.1016\/j.medcli.2026.107537_bib0070","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/S1473-3099(19)30573-0","article-title":"Long-term impact of an educational antimicrobial stewardship programme in primary care on infections caused by extended-spectrum \u03b2-lactamase-producing Escherichia coli in the community: an interrupted time-series analysis","volume":"20","author":"Pe\u00f1alva","year":"2020","journal-title":"Lancet Infect Dis."},{"key":"10.1016\/j.medcli.2026.107537_bib0075","first-page":"238","article-title":"Antimicrobial stewardship in hospitals: Expert recommendation guidance document for activities in specific populations, syndromes and other aspects (PROA-2) from SEIMC, SEFH","volume":"41","author":"Cercenado","year":"2023","journal-title":"SEMPSPGS, SEMICYUC and SEIP. Enferm Infecc Microbiol Clin (Engl Ed)."},{"key":"10.1016\/j.medcli.2026.107537_bib0080","doi-asserted-by":"crossref","first-page":"2897","DOI":"10.1093\/cid\/ciz1183","article-title":"Impact of a Comprehensive Antimicrobial Stewardship Program on Institutional Burden of Antimicrobial Resistance: A 14-Year Controlled Interrupted Time-series Study","volume":"71","author":"Peragine","year":"2020","journal-title":"Clin Infect Dis."},{"key":"10.1016\/j.medcli.2026.107537_bib0085","doi-asserted-by":"crossref","first-page":"102753","DOI":"10.1016\/j.jiac.2025.102753","article-title":"Global impact of antimicrobial stewardship programs in Healthcare: An umbrella review of effectiveness, cost-efficiency, and implementation strategies","volume":"31","author":"Krishnamoorthy","year":"2025","journal-title":"J Infect Chemother."},{"key":"10.1016\/j.medcli.2026.107537_bib0090","doi-asserted-by":"crossref","first-page":"e573","DOI":"10.1016\/S2352-3026(17)30211-9","article-title":"Optimisation of empirical antimicrobial therapy in patients with haematological malignancies and febrile neutropenia (How Long study): an open-label, randomised, controlled phase 4 trial","volume":"4","author":"Aguilar-Guisado","year":"2017","journal-title":"Lancet Haematol."},{"key":"10.1016\/j.medcli.2026.107537_bib0095","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/S1473-3099(25)00619-X","article-title":"Empirical and targeted antimicrobial therapy in patients with febrile neutropenia and haematological malignancy or after haematopoietic cell transplantation: recommendations from the 10th European Conference on Infections in Leukaemia","volume":"26","author":"Averbuch","year":"2026","journal-title":"Lancet Infect Dis."},{"key":"10.1016\/j.medcli.2026.107537_bib0100","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1016\/S0140-6736(21)00313-5","article-title":"Discontinuing \u03b2-lactam treatment after 3 days for patients with community-acquired pneumonia in non-critical care wards (PTC): a double-blind, randomised, placebo-controlled, non-inferiority trial","volume":"397","author":"Dinh","year":"2021","journal-title":"Lancet."},{"key":"10.1016\/j.medcli.2026.107537_bib0105","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/S1473-3099(24)00456-0","article-title":"The evidence base for the optimal antibiotic treatment duration of upper and lower respiratory tract infections: an umbrella review","volume":"25","author":"Kuijpers","year":"2025","journal-title":"Lancet Infect Dis."},{"key":"10.1016\/j.medcli.2026.107537_bib0110","doi-asserted-by":"crossref","first-page":"e061023","DOI":"10.1136\/bmjopen-2022-061023","article-title":"Optimal duration of antibiotic treatment for community-acquired pneumonia in adults: a systematic review and duration-effect meta-analysis","volume":"13","author":"Furukawa","year":"2023","journal-title":"BMJ Open."},{"key":"10.1016\/j.medcli.2026.107537_bib0115","first-page":"24","article-title":"Diagnosis and Management of Community-acquired Pneumonia. An Official American Thoracic Society Clinical Practice Guideline","volume":"212","author":"Jones","year":"2026","journal-title":"Am J Respir Crit Care Med."},{"key":"10.1016\/j.medcli.2026.107537_bib0120","first-page":"ciaf462","article-title":"Clinical Practice Guideline by Infectious Diseases Society of America (IDSA): 2025 Guideline on Management and Treatment of Complicated Urinary Tract Infections: Duration of Antibiotics for Complicated UTI","author":"Trautner","year":"2025","journal-title":"Clin Infect Dis."},{"key":"10.1016\/j.medcli.2026.107537_bib0125","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1016\/j.cmi.2025.04.008","article-title":"Short vs. long antibiotic treatment for pyelonephritis and complicated urinary tract infections: a living systematic review and meta-analysis of randomized controlled trials","volume":"31","author":"Zahavi","year":"2025","journal-title":"Clin Microbiol Infect."},{"key":"10.1016\/j.medcli.2026.107537_bib0130","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1001\/archinte.164.15.1669","article-title":"Comparison of short-course (5 days) and standard (10 days) treatment for uncomplicated cellulitis","volume":"164","author":"Hepburn","year":"2004","journal-title":"Arch Intern Med."},{"key":"10.1016\/j.medcli.2026.107537_bib0135","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1001\/jama.2016.8825","article-title":"Cellulitis: A Review","volume":"316","author":"Raff","year":"2016","journal-title":"JAMA."},{"key":"10.1016\/j.medcli.2026.107537_bib0140","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1089\/sur.2022.294","article-title":"Defining the Optimal Antibiotic Duration in Necrotizing Skin and Soft Tissue Infections: Clinical Experience from a Quaternary Referral Center","volume":"24","author":"Horn","year":"2023","journal-title":"Surg Infect (Larchmt)."},{"key":"10.1016\/j.medcli.2026.107537_bib0145","doi-asserted-by":"crossref","first-page":"176","DOI":"10.14309\/ajg.0000000000002499","article-title":"Conventional vs Short Duration of Antibiotics in Patients With Moderate or Severe Cholangitis: Noninferiority Randomized Trial","volume":"119","author":"Srinu","year":"2024","journal-title":"Am J Gastroenterol."},{"key":"10.1016\/j.medcli.2026.107537_bib0150","doi-asserted-by":"crossref","first-page":"482","DOI":"10.3390\/antibiotics12030482","article-title":"Acute Cholecystitis from Biliary Lithiasis: Diagnosis. Management and Treatment","volume":"12","author":"Costanzo","year":"2023","journal-title":"Antibiotics (Basel)."},{"key":"10.1016\/j.medcli.2026.107537_bib0155","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1093\/cid\/ciad670","article-title":"Emulating a Target Trial of Shorter Compared to Longer Course of Antibiotic Therapy for Gram-Negative Bacteremia","volume":"78","author":"Tingsg\u00e5rd","year":"2024","journal-title":"Clin Infect Dis."},{"key":"10.1016\/j.medcli.2026.107537_bib0160","doi-asserted-by":"crossref","first-page":"103397","DOI":"10.1016\/j.eclinm.2025.103397","article-title":"Shorter versus longer-duration antibiotic treatments for immunocompetent patients with bloodstream infections: a systematic review and meta-analysis","volume":"86","author":"Liu","year":"2025","journal-title":"EClinicalMedicine."},{"key":"10.1016\/j.medcli.2026.107537_bib0165","doi-asserted-by":"crossref","first-page":"101762","DOI":"10.1016\/j.eclinm.2022.101750","article-title":"Duration of antibiotic treatment for Gram-negative bacteremia \u2013 Systematic review and individual participant data (IPD) meta-analysis.","volume":"55","author":"Turjeman","year":"2023","journal-title":"eClinicalMedicine."},{"key":"10.1016\/j.medcli.2026.107537_bib0170","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1016\/j.cmi.2021.09.001","article-title":"Seven-versus 14-day course of antibiotics for the treatment of bloodstream infections by Enterobacterales: a randomized, controlled trial","volume":"28","author":"Molina","year":"2022","journal-title":"Clin Microbiol Infect."},{"key":"10.1016\/j.medcli.2026.107537_bib0175","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1056\/NEJMoa2404991","article-title":"Antibiotic Treatment for 7 versus 14 Days in Patients with Bloodstream Infections","volume":"392","author":"Daneman","year":"2025","journal-title":"N Engl J Med."},{"key":"10.1016\/j.medcli.2026.107537_bib0180","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1093\/jac\/dkab358","article-title":"Short versus prolonged courses of antimicrobial therapy for patients with uncomplicated Pseudomonas aeruginosa bloodstream infection: a retrospective study","volume":"77","author":"Bae","year":"2021","journal-title":"J Antimicrob Chemother."},{"key":"10.1016\/j.medcli.2026.107537_bib0185","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.jhin.2024.04.007","article-title":"Short versus prolonged duration of therapy for Pseudomonas aeruginosa bacteraemia: a systematic review and meta-analysis","volume":"148","author":"Ranganath","year":"2024","journal-title":"J Hosp Infect."},{"key":"10.1016\/j.medcli.2026.107537_bib0190","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1093\/cid\/ciy1054","article-title":"Seven Versus 14 Days of Antibiotic Therapy for Uncomplicated Gram-negative Bacteremia: A Noninferiority Randomized Controlled Trial","volume":"69","author":"Yahav","year":"2019","journal-title":"Clin Infect Dis."},{"key":"10.1016\/j.medcli.2026.107537_bib0195","doi-asserted-by":"crossref","first-page":"6905","DOI":"10.3390\/ijms26146905","article-title":"Antibiotic Therapy Duration for Multidrug-Resistant Gram-Negative Bacterial Infections: An Evidence-Based Review","volume":"26","author":"Marino","year":"2025","journal-title":"Int J Mol Sci."},{"key":"10.1016\/j.medcli.2026.107537_bib0200","doi-asserted-by":"crossref","first-page":"e0277333","DOI":"10.1371\/journal.pone.0277333","article-title":"Study protocol for a randomized clinical trial to assess 7 versus 14-days of treatment for Pseudomonas aeruginosa bloodstream infections (SHORTEN-2 trial)","volume":"17","author":"Molina","year":"2022","journal-title":"PLOS ONE."},{"key":"10.1016\/j.medcli.2026.107537_bib0205","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1001\/jama.2025.4288","article-title":"Management of Staphylococcus aureus Bacteremia: A Review","volume":"334","author":"Tong","year":"2025","journal-title":"JAMA."},{"key":"10.1016\/j.medcli.2026.107537_bib0210","doi-asserted-by":"crossref","first-page":"e00026","DOI":"10.1128\/MMBR.00026-19","article-title":"Staphylococcal Biofilm Development: Structure. Regulation, and Treatment Strategies","volume":"84","author":"Schilcher","year":"2020","journal-title":"Microbiol Mol Biol Rev."},{"key":"10.1016\/j.medcli.2026.107537_bib0215","doi-asserted-by":"crossref","first-page":"106352","DOI":"10.1016\/j.ijantimicag.2021.106352","article-title":"Revisiting the epidemiology of bloodstream infections and healthcare-associated episodes: results from a multicentre prospective cohort in Spain (PRO-BAC Study)","volume":"58","author":"P\u00e9rez-Crespo","year":"2021","journal-title":"Int J Antimicrob Agents."},{"key":"10.1016\/j.medcli.2026.107537_bib0220","doi-asserted-by":"crossref","first-page":"1868","DOI":"10.1093\/cid\/ciz112","article-title":"Changing Characteristics of Staphylococcus aureus Bacteremia: Results From a 21-Year, Prospective","volume":"69","author":"Souli","year":"2019","journal-title":"Longitudinal Study. Clin Infect Dis."},{"key":"10.1016\/j.medcli.2026.107537_bib0225","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/j.jinf.2013.10.015","article-title":"Staphylococcus aureus bloodstream infection: a pooled analysis of five prospective, observational studies","volume":"68","author":"Kaasch","year":"2014","journal-title":"J Infect."},{"key":"10.1016\/j.medcli.2026.107537_bib0230","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1093\/cid\/ciy1000","article-title":"Incidence and Outcomes of Staphylococcus aureus Bacteriuria: A Population-based Study","volume":"69","author":"Stokes","year":"2019","journal-title":"Clin Infect Dis."},{"key":"10.1016\/j.medcli.2026.107537_bib0235","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1093\/cid\/ciae338","article-title":"Clinical Subphenotypes of Staphylococcus aureus Bacteremia","volume":"79","author":"Swets","year":"2024","journal-title":"Clin Infect Dis."},{"key":"10.1016\/j.medcli.2026.107537_bib0240","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1056\/NEJMoa1808312","article-title":"Partial Oral versus Intravenous Antibiotic Treatment of Endocarditis.","volume":"380","author":"Iversen","year":"2019","journal-title":"N Engl J Med."},{"key":"10.1016\/j.medcli.2026.107537_bib0245","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/S1473-3099(23)00756-9","article-title":"Efficacy and safety of an early oral switch in low-risk Staphylococcus aureus bloodstream infection (SABATO): an international, open-label, parallel-group, randomised, controlled, non-inferiority trial","volume":"24","author":"Kaasch","year":"2024","journal-title":"Lancet Infect Dis."},{"key":"10.1016\/j.medcli.2026.107537_bib0250","doi-asserted-by":"crossref","first-page":"e0022024","DOI":"10.1128\/aac.00220-24","article-title":"Antibiotic duration and route for treatment of adults with uncomplicated streptococcal bloodstream infections: a retrospective study in a large healthcare system","volume":"68","author":"Clutter","year":"2024","journal-title":"Antimicrob Agents Chemother."},{"key":"10.1016\/j.medcli.2026.107537_bib0255","first-page":"1203","article-title":"Treatment duration for central line-associated infection caused by Enterococcus spp.: a retrospective evaluation of a multicenter cohort","volume":"41","author":"Rosselli Del Turco","year":"2022","journal-title":"Eur J Clin Microbiol Infect Dis."},{"key":"10.1016\/j.medcli.2026.107537_bib0260","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.cmi.2022.08.023","article-title":"Short-course versus long-course antibiotic treatment for uncomplicated vancomycin-resistant enterococcal bacteraemia: a retrospective multicentre cohort study","volume":"29","author":"Bahrs","year":"2023","journal-title":"Clin Microbiol Infect."},{"key":"10.1016\/j.medcli.2026.107537_bib0265","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1007\/s10096-025-05348-6","article-title":"Short course of antimicrobial treatment for uncomplicated enterococcal bacteremia","volume":"45","author":"Zimmermann","year":"2026","journal-title":"Eur J Clin Microbiol Infect Dis."},{"key":"10.1016\/j.medcli.2026.107537_bib0270","doi-asserted-by":"crossref","first-page":"e075699","DOI":"10.1136\/bmjopen-2023-075699","article-title":"Randomised, open-label, non-inferiority clinical trial on the efficacy and safety of a 7-day vs 14-day course of antibiotic treatment for uncomplicated enterococcal bacteraemia: the INTENSE trial protocol","volume":"13","author":"Maldonado","year":"2023","journal-title":"BMJ Open."},{"key":"10.1016\/j.medcli.2026.107537_bib0275","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.riam.2013.10.001","article-title":"Epidemiology of candidaemia and invasive candidiasis. A changing face","volume":"31","author":"Quind\u00f3s","year":"2014","journal-title":"Rev Iberoam Micol."},{"key":"10.1016\/j.medcli.2026.107537_bib0280","doi-asserted-by":"crossref","first-page":"e280","DOI":"10.1016\/S1473-3099(24)00749-7","article-title":"Global guideline for the diagnosis and management of candidiasis: an initiative of the ECMM in cooperation with ISHAM and ASM","volume":"25","author":"Cornely","year":"2025","journal-title":"Lancet Infect Dis."},{"key":"10.1016\/j.medcli.2026.107537_bib0285","doi-asserted-by":"crossref","first-page":"ofac656","DOI":"10.1093\/ofid\/ofac656","article-title":"Short Course of Antifungal Therapy in Patients With Uncomplicated Candida Bloodstream Infection: Another Case of Less Is More in the Clinical Setting?","volume":"10","author":"Vena","year":"2023","journal-title":"Open Forum Infect Dis."},{"key":"10.1016\/j.medcli.2026.107537_bib0290","doi-asserted-by":"crossref","first-page":"2160","DOI":"10.1001\/jama.2020.6348","article-title":"Effect of C-Reactive Protein-Guided Antibiotic Treatment Duration, 7-Day Treatment, or 14-Day Treatment on 30-Day Clinical Failure Rate in Patients With Uncomplicated Gram-Negative Bacteremia: A Randomized Clinical Trial","volume":"323","author":"von Dach","year":"2020","journal-title":"JAMA."}],"container-title":["Medicina Cl\u00ednica"],"original-title":[],"language":"es","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025775326001879?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025775326001879?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T03:54:10Z","timestamp":1788148450000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0025775326001879"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":58,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["S0025775326001879"],"URL":"https:\/\/doi.org\/10.1016\/j.medcli.2026.107537","relation":{},"ISSN":["0025-7753"],"issn-type":[{"value":"0025-7753","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Optimizaci\u00f3n de la duraci\u00f3n del tratamiento antimicrobiano en la era de los programas de optimizaci\u00f3n de antimicrobianos","name":"articletitle","label":"Article Title"},{"value":"Medicina Cl\u00ednica","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.medcli.2026.107537","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Espa\u00f1a, S.L.U. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"107537"}}